Monday, September 22, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

UBS Analyst Karl Keirstead Maintains Neutral Rating on Xometry with Lowered Price Target

Elaine Mendonca by Elaine Mendonca
March 13, 2024
in Breaking News
0
DVY stock news
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

UBS analyst Karl Keirstead is keeping a Neutral rating on Xometry (NASDAQ: XMTR) as of March 13, 2024. He has revised the price target down to $21 from $22, citing a softer revenue forecast for the company.

Keirstead, known for his accuracy in stock analysis, covers 29 stocks with a success rate of 65.71% and an average return of 18.8%.

XMTR Stock Plummets on March 13, 2024, Trading Near 52-Week Low

On March 13, 2024, XMTR stock experienced a decline in its performance, trading near the bottom of its 52-week range and below its 200-day simple moving average. The stock opened at $17.91, which was $0.16 lower than its previous close. Throughout the trading day, the price of XMTR shares continued to drop, decreasing by $0.50 or 2.77% since the market last closed.

XMTR Stock Analysis: Promising Revenue Growth and Improved EPS on March 13, 2024

On March 13, 2024, XMTR stock showed promising performance based on the financial data provided by CNN Money. The company reported a total revenue of $463.41 million for the past year, showing a 21.61% increase compared to the previous year. In the fourth quarter, XMTR generated $128.15 million in total revenue, which represents a 7.75% increase from the previous quarter.

Despite the positive revenue growth, XMTR reported a net income of -$67.47 million for the year, with a smaller net loss of -$10.55 million in the fourth quarter. The net income increased by 11.25% compared to the previous year, but remained stable from the previous quarter. Earnings per share (EPS) also improved, with a reported EPS of -$1.41 for the year and -$0.22 for the fourth quarter. The EPS increased by 12.65% since last year and by 12.42% since the previous quarter.

Overall, XMTR stock showed resilience and growth in its financial performance on March 13, 2024. The increase in total revenue and EPS indicates that the company is on the right track towards profitability. Investors may view these positive financial indicators as a sign of potential future growth and may consider investing in XMTR stock. However, it is important to conduct further research and analysis before making any investment decisions.

Tags: XMTR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Cryptocurrency Stock Market Today

Navigating Uncertainties The Death Cross in Crypto Mining Stocks

Investings on laptops and finances

Analyzing GoHealths Earnings and Stock Performance

Renewable energy

Montauk Renewables Earnings Preview and Stock Analysis

Recommended

Emergent BioSolutions Stock

A Tale of Two Realities: Emergent BioSolutions’ Social Mission and Financial Strain

4 weeks ago
Food Retailers Stock Bull Market

JP Morgan Analyst Maintains Neutral Rating on Tyson Foods with Revised Price Target

2 years ago
MMM stock news

Bearish Sentiment Surrounds Air Lease NYSE AL Trading

2 years ago
QuantumScape Stock

QuantumScape Leadership Executes Major Stock Sales, Raising Investor Concerns

5 days ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

AAPL Adobe Alibaba Alphabet Amazon AMD AMZN Apple ASML BA BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv Hims & Hers IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Opendoor Oracle Oxford Lane Capital Palantir PayPal Pepsi Red Cat Robinhood Rocket Lab USA Salesforce Strategy Tesla TSLA Unitedhealth Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Ubiquiti Shares Reach New Heights on Product Expansion Momentum

BioNTech’s Strategic Pivot: From Pandemic Success to Oncology Innovation

Leadership Crisis at Nestlé Sparks Investor Concerns

Standex Shares Plunge Amid Technical Warnings and Insider Selling

Navigating Credit Headwinds: Synchrony’s Strategic Expansion Amid Sector Challenges

Tech Sector Surge: AI and Cloud Computing Fuel Vanguard ETF’s Record Run

Trending

Pfizer Stock
Healthcare

Pfizer’s Strategic Gambit: A $7.3 Billion Entry into the Weight-Loss Arena

by Dieter Jaworski
September 22, 2025
0

In a move signaling its serious intent to capture a share of the lucrative anti-obesity drug market,...

Nike Stock

Nike Shares Face Critical Earnings Test

September 22, 2025
Tutor Perini Stock

Insider Sales at Tutor Perini Coincide with Stock Peak

September 22, 2025
Ubiquiti Stock

Ubiquiti Shares Reach New Heights on Product Expansion Momentum

September 22, 2025
BioNTech Stock

BioNTech’s Strategic Pivot: From Pandemic Success to Oncology Innovation

September 22, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Pfizer’s Strategic Gambit: A $7.3 Billion Entry into the Weight-Loss Arena
  • Nike Shares Face Critical Earnings Test
  • Insider Sales at Tutor Perini Coincide with Stock Peak

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com